MA29280B1 - Forme posologique orale contenant de la rosiglitazone - Google Patents

Forme posologique orale contenant de la rosiglitazone

Info

Publication number
MA29280B1
MA29280B1 MA30181A MA30181A MA29280B1 MA 29280 B1 MA29280 B1 MA 29280B1 MA 30181 A MA30181 A MA 30181A MA 30181 A MA30181 A MA 30181A MA 29280 B1 MA29280 B1 MA 29280B1
Authority
MA
Morocco
Prior art keywords
dosage form
oral dosage
release
form containing
composition
Prior art date
Application number
MA30181A
Other languages
English (en)
Inventor
Vincenzo Re
Original Assignee
Sb Pharmco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sb Pharmco Inc filed Critical Sb Pharmco Inc
Publication of MA29280B1 publication Critical patent/MA29280B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'INVENTION CONCERNE UNE FORME POSOLOGIQUE ORALE COMPRENANT DES GRANULES D'UNE PREMIÈRE COMPOSITION ET DES GRANULES D'UNE SECONDE COMPOSITION, CHAQUE COMPOSITION CONTENANT UNE 5-[4-[2-(N-MÉTHYL-N-(2 PYRIDYL)AMINO)ÉTHOXY]BENZYL]THIAZOLIDINE-2,4-DIONE OU UN SEL OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CETTE DERNIÈRE ET UN VECTEUR PHARMACEUTIQUEMENT ACCEPTABLE POUR LEDIT COMPOSÉ, LES PREMIÈRE ET SECONDE COMPOSITIONS ÉTANT CONÇUES POUR LIBÉRER LE MÉDICAMENT À DIFFÉRENTES VITESSES DE LIBÉRATION LORS DE L'ADMINISTRATION, DE PRÉFÉRENCE DE SORTE QUE LA VITESSE DE LIBÉRATION DU MÉDICAMENT DE LA FORME POSOLOGIQUE EST SENSIBLEMENT INDÉPENDANTE DU PH. CETTE INVENTION CONCERNE ÉGALEMENT UN PROCÉDÉ DE PRÉPARATION D'UNE FORME POSOLOGIQUE DE CE TYPE ET L'UTILISATION DE CETTE FORME POSOLOGIQUE EN MÉDECINE.
MA30181A 2005-02-07 2007-08-31 Forme posologique orale contenant de la rosiglitazone MA29280B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0502479.9A GB0502479D0 (en) 2005-02-07 2005-02-07 Novel compositions

Publications (1)

Publication Number Publication Date
MA29280B1 true MA29280B1 (fr) 2008-02-01

Family

ID=34355902

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30181A MA29280B1 (fr) 2005-02-07 2007-08-31 Forme posologique orale contenant de la rosiglitazone

Country Status (16)

Country Link
US (1) US20080139624A1 (fr)
EP (1) EP1845977A1 (fr)
JP (1) JP2008529984A (fr)
KR (1) KR20070104392A (fr)
CN (1) CN101155585A (fr)
AU (1) AU2006210135A1 (fr)
BR (1) BRPI0606768A2 (fr)
CA (1) CA2595409A1 (fr)
EA (1) EA200701680A1 (fr)
GB (1) GB0502479D0 (fr)
IL (1) IL184787A0 (fr)
MA (1) MA29280B1 (fr)
MX (1) MX2007009493A (fr)
NO (1) NO20074514L (fr)
TW (1) TW200640455A (fr)
WO (1) WO2006082089A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
JP2010513324A (ja) * 2006-12-21 2010-04-30 アルファファーム ピーティーワイ リミテッド 医薬化合物および医薬組成物
NZ588407A (en) 2008-03-11 2012-07-27 Takeda Pharmaceutical Orally-disintegrating solid preparation
US20100068233A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Modifiable dosage form
US20100068275A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Personalizable dosage form
US20100068235A1 (en) * 2008-09-16 2010-03-18 Searete LLC, a limited liability corporation of Deleware Individualizable dosage form
US20100068254A1 (en) * 2008-09-16 2010-03-18 Mahalaxmi Gita Bangera Modifying a medicament availability state of a final dosage form
US20100068283A1 (en) 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex VIVO modifiable particle or polymeric material medicament carrier
US20100069887A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Multiple chamber ex vivo adjustable-release final dosage form
US20100069821A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable medicament release-sites final dosage form
CN109481419B (zh) * 2019-01-16 2021-04-02 中国人民解放军陆军军医大学第一附属医院 一种罗格列酮纳米制剂及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US8802139B2 (en) * 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
TW200517127A (en) * 2003-08-07 2005-06-01 Sb Pharmco Inc Novel composition
EP1732513A2 (fr) * 2003-12-31 2006-12-20 Alpharma, Inc. Preparations de rosiglitazone

Also Published As

Publication number Publication date
BRPI0606768A2 (pt) 2009-07-14
TW200640455A (en) 2006-12-01
EP1845977A1 (fr) 2007-10-24
EA200701680A1 (ru) 2007-12-28
NO20074514L (no) 2007-09-05
US20080139624A1 (en) 2008-06-12
WO2006082089A1 (fr) 2006-08-10
AU2006210135A1 (en) 2006-08-10
JP2008529984A (ja) 2008-08-07
GB0502479D0 (en) 2005-03-16
KR20070104392A (ko) 2007-10-25
CN101155585A (zh) 2008-04-02
CA2595409A1 (fr) 2006-08-10
IL184787A0 (en) 2007-12-03
MX2007009493A (es) 2007-09-19

Similar Documents

Publication Publication Date Title
MA29280B1 (fr) Forme posologique orale contenant de la rosiglitazone
KR940006590A (ko) 알쯔하이머 질환 치료용 및 혈당저하제로서 유용한 화합물
NO20074407L (no) Oral doseringsform omfattende rosiglitazon
AP1545A (en) Hydrochloride salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione.
EP1551411A2 (fr) Methodes et compositions synergetiques pour le traitement du cancer
HRP20030339A2 (en) Oral dosage self-emulsifying formulations of pyranone protease inhibitors
MA26511A1 (fr) Compositions pharmaceutiques comprenant de la 5-(4-(2-(n-methyl-n-(2-pyridyl) amino) ethoxy) benzyl)-thiazolidine-2,4-dione et de l'insuline pour une methode de traitement.
SE9902935D0 (sv) Pharmaceutical compositions
OA13233A (en) Novel composition comprising rosiglitazone and another antidiabetic agent.
AR045330A1 (es) Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla
AP1562A (en) Thiazolidinedione derivatives and its use as antidiabetic.
ATE337313T1 (de) 5-4'-2'-(n-methyl-n-(2-pyridyl)amino) ethoxy)benzyl)thiazolidin-2,4-dion mesylatsalz
AP1715A (en) The hydrochloride salt of 5-[ 4 -[2 -(n-methyl-n- (2-pyridyl) amino) ethoxy]benzyl]thiazolidine -2,4-dione
AU2002343052A1 (en) Rosiglitazone edisylates and their use as antidiabetics
AP1814A (en) Tartrate salts of thiazolidinedione derivative.
WO2000063206A3 (fr) Nouvelle substance pharmaceutique
MXPA02012100A (es) Sal de tiazodilindiona para el tratamiento de la diabetes mellitus.
AP1738A (en) Sodium salts of 5-[4-[2-(N-Methyl -N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione.
AP1785A (en) Tartrate salt of thiazolidinedione derivative.
AP2003002737A0 (en) Tartrate salts of thiazolidinedione derivatives
GB0021784D0 (en) Novel pharmaceutical
CY1107767T1 (el) Παραγωγο θειαζολιδινοδιονης και χρηση αυτου σαν αντιδιαβητικο
CY1107421T1 (el) Τρυγικα αλατα παραγωγου θειαζολιδινοδιονης
RS50130B (sr) Farmaceutska kompozicija 5-(4-(2-(n-metil-n-(2-piridil)amino)etoksi)benzil) tiazolidin-2,4-diona
AP2002002684A0 (en) 5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2-pyridyl) amino) ethoxy)benzyl) thiazolidine-2,4-dione hydriodide as pharmaceutical